

Highly diastereoselective Staudinger reaction on 5,6-dihydropyrazin-2-(1*H*)-ones. Synthesis of enantiopure fused oxopiperazino- β -lactams

Alma Viso,* Roberto Fernández de la Pradilla* and Aida Flores

Instituto de Química Orgánica, CSIC, Juan de la Cierva, 3; 28006 Madrid, Spain

Received 11 August 2006; revised 3 October 2006; accepted 9 October 2006

Available online 30 October 2006

Abstract—The highly diastereoselective synthesis of fused oxopiperazino- β -lactams **2** by Staudinger reaction between functionalized ketenes and 5,6-dihydropyrazin-2(1*H*)-ones **1** has been carried out. Further cleavage of the β -lactam ring produced 2-oxopiperazine-3-acetic acid derivatives **7** with no epimerization and in good yields.

© 2006 Elsevier Ltd. All rights reserved.

The oxopiperazine ring is a well established conformationally constrained peptidomimetic, therefore, many efforts have aimed to prepare these products with stereocontrol.¹ In particular, 2-oxopiperazine-3-acetic acid methyl ester has been designed as cyclic template bearing an aspartic acid side chain.² Furthermore, related compounds containing 2-oxopiperazine-3-acetic acid subunits have shown activity as aspartate transcarbamoylase inhibitors, and as antagonists of the glycoprotein IIb/IIIa useful for the treatment of thrombotic diseases.³ Frequently, the enantioselective synthetic approaches to 3-substituted 2-oxopiperazines rely on natural aminoacids and are not fully useful for the straightforward synthesis of highly substituted derivatives.

β -Lactams continue to attract attention from chemists due to their antibiotic properties; in addition, in recent years the β -lactam skeleton has found broad applicability as a synthon to prepare a wide range of molecules.⁴ The Staudinger reaction between imines and ketenes is one of the most efficient methods to prepare enantiopure 2-azetidiones. In particular, most of the reports on the synthesis of bicyclic β -lactams are focused on initial [2+2] cycloaddition of acyclic imines and ketenes and further cyclization of the groups pending of the β -lactam.⁵ In contrast, reports focused on the diastereo-


selective synthesis of enantiopure β -lactams from cyclic imines are scarce and often limited to the use of enantiopure acid chlorides as the source of asymmetric induction.⁶

Within a program focused on the discovery of bioactive piperazines⁷ and in connection with our studies on the development of efficient routes to highly substituted enantiopure piperazines from sulfinimines,⁸ we examined the stereocontrolled addition of nucleophiles onto 5,6-dihydropyrazin-2(1*H*)-ones, **A**. A completely stereoselective and high-yielding allylation^{8b} was achieved under Barbier conditions (**B**) using $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ as additive and this would be a suitable route to an acetate group by oxidation. Encouraged by these results and seeking an alternative access to 2-oxopiperazine-3-acetic acid derivatives, we submitted substrates **A** to the parallel Reformatsky procedure using methyl α -bromoacetate. However, 5,6-dihydropyrazin-2(1*H*)-ones **A** were unreactive under these conditions and the addition of preformed organozinc reagents such as 4-ethoxy-4-oxobutylzinc bromide also resulted ineffective (**Scheme 1**). At this point, we planned an alternative strategy for the synthesis of these compounds. We envisioned a new approach by means of a diastereoselective Staudinger reaction onto 5,6-dihydropyrazin-2(1*H*)-ones **A**, to produce fused oxo-piperazino- β -lactams **C** that could be suitable precursors to highly substituted enantiopure piperazines.


Initially we examined the reaction between **1a** and an excess of phthalimidoacetyl chloride in the presence of

Keywords: β -Lactams; Piperazines; Asymmetric synthesis.

* Corresponding authors. Tel.: +34 91 5618806; fax: +34 91 5644853 (A.V.); e-mail: iqov379@iqog.csic.es



Scheme 1.



Scheme 2.

triethylamine, in CH_2Cl_2 and at room temperature and we found an excellent yield of β -lactam **2a** as a single diastereoisomer (Scheme 2, Table 1, entry 1).⁹ Under









similar reaction conditions, a good yield of acetoxy β -lactam **2b** (entry 2) was obtained, however other acetyl chlorides (benzyloxy-, chloro-, and 2,5-dimethoxyphenyl-, entries 3, 5, and 8) did not render a complete [2+2] cycloaddition yielding substantial amounts of monocyclic intermediates **3c–e**, each of them as a single isomer and generated by addition of water to the acyliminium intermediates during the aqueous work-up.¹⁰

To improve the yields of β -lactams, we changed the reaction conditions to toluene at 80°C and good yields of chloro- and 2,5-dimethoxyphenyl β -lactams **2c** and **2e** were obtained while maintaining complete diastereoselectivity (entries 4 and 9). Upon these conditions, benzyloxyacetyl chloride led to an 82:12 mixture of diastereoisomeric β -lactams (80%) along with 14% of **3d** which incorporates two molecules of the starting acid chloride. A decrease in the reaction temperature allowed for the synthesis of **2d** as a single diastereomer but again 27% of **3d** was isolated in this experiment (entries 6 and 7). To extend the scope of this procedure, we examined the behavior of 5,6-dihydropyrazin-2(1*H*)-one **1b**, with the imine flanked by an aromatic group ($\text{R}^1 = 1$ -naphthyl). Entries 12–14 show that **1b** underwent a highly diastereoselective Staudinger reaction providing β -lactams **2g–i** in good yield under these conditions.¹¹ Efforts to prepare 3,3-disubstituted β -lactams and 3-alkyl/vinyl

Table 1. Synthesis of piperazino- β -lactams **2a–i** produced via Scheme 2


Entry	1	Conditions	2 (Yield %)	3 (Yield %)
1	1a	PhthNCH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) CH ₂ Cl ₂ , 0 °C–rt, 15 h	2a (99%)	—
2	1a	AcOCH ₂ COCl (2.30 equiv), NEt ₃ (6.4 equiv) CH ₂ Cl ₂ , 0 °C–rt, 28 h	2b (85%)	—
3	1a	ClCH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) CH ₂ Cl ₂ , 0 °C–rt, 19 h	2c (36%)	3c (60%)
4	1a	Toluene, 80 °C, 4 h 30 min	2c (74%)	—
5	1a	BnOCH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) CH ₂ Cl ₂ , 0 °C–rt, 18 h	2d (57%)	3d (21%)
6	1a	Toluene, 40–80 °C, 4 h	2d (60%)	3d (27%)
7	1a	Toluene, 80 °C, 1 h	2d (82:12, 80%)	3d (14%)

Table 1 (continued)

Entry	1	Conditions	2 (Yield %)	3 (Yield %)
8	1a	2,5-(CH ₃ O) ₂ -C ₆ H ₃ CH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) CH ₂ Cl ₂ , 0 °C–rt–Δ, 51 h	 2e (31%)	 3e (54%)
9	1a	Toluene, 80 °C, 1 h 15 min	2e (74%)	—
10	1a	Cl ₂ CHCOCl (2.0 equiv), NEt ₃ (4.0 equiv) toluene, rt, 1 h	 2f (4%)	 3f (75%)
11	1a	Cl ₂ CHCOCl (1.72 equiv), NEt ₃ (4.8 equiv) toluene, 80 °C, 4 h	—	 3f' (80%)
12	1b	PhthNCH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) toluene, 80 °C, 19 h	 2g (71%)	—
13	1b	AcOCH ₂ COCl (1.72 equiv), NEt ₃ (4.8 equiv) CH ₂ Cl ₂ , 0 °C–rt, 20 h 30 min	 2h (73%)	—
14	1b	2,5-(CH ₃ O) ₂ -C ₆ H ₃ CH ₂ COCl (3.40 equiv), NEt ₃ (9.60 equiv) toluene, 80 °C, 18 h	 2i (71%)	—

β -lactams were unsuccessful under thermodynamic and kinetic conditions. When *i*-butyryl chloride, *n*-butyryl chloride and 3-methylbut-2-enoyl chloride were used as ketene precursors, complex mixtures of N-acylated compounds were isolated. In contrast, the reaction of **1a** with dichloroacetyl chloride in toluene at room temperature led to N-acylated derivative **3f** (75%), along with a trace amount of β -lactam **2f** (4%). Increasing the temperature led to the isolation of **3f'** (80%) with loss of the silyl protecting group (entries 10 and 11).¹²


The structural assignment of the bicyclic β -lactams **2a–i** was based on spectroscopic data (Scheme 3). The trans relative stereochemistry was easily determined by the small coupling constant between H-3 and H-6 ranging from 1.9 to 2.6 Hz. The absolute configuration was established by 2D-NOESY experiments which showed cross points between H-6 and protons of R¹.¹³ The trans stereochemical outcome could be rationalized in terms of an *exo* approach, which places the electrodonating



Scheme 3.

ketene substituent (R²) outward without further isomerization of the imine. With respect to the diastereofacial selectivity, the pseudo axial arrangement of R¹ probably blocks the β -face of the iminium intermediate and therefore cyclization takes place by the less hindered convex face.¹⁴

In addition, we examined the reactivity of oxopiperazino- β -lactams **2** (Scheme 4). Thus, **2d** underwent smooth hydrogenation when EtOAc was used as a solvent ren-



Scheme 4. Reagents and conditions: (a) Pd-C (10%), H_2 , 45 psi, EtOAc, rt, (b) $\text{BH}_3\text{-SMe}_2$, THF, Δ ; then 0.2 N HCl, Δ , (c) TMSCl, MeOH, rt.

dering α -hydroxy- β -lactam **4** in 75% yield. The use of nucleophilic solvents as methanol should be avoided due to the lability of these bicyclic β -lactams. We have also explored the behavior of these β -lactams under reductive conditions. The treatment of **2e** with $\text{BH}_3\text{-SMe}_2$ in THF under reflux gave rise to a mixture of the bicyclic azetidine **5** (39%) and piperazinyl ethanol **6** (37%). Finally, treatment of **2a** and **2i** with trimethylchlorosilane in methanol smoothly produced the cleavage of the β -lactam ring with simultaneous deprotection of the hydroxymethyl group to give 2-oxopiperazine-3-acetic acid methyl esters **7a** and **7i** in good yields.¹⁵

In conclusion, we have developed a general method to prepare fused oxopiperazino- β -lactams **2** by reaction between functionalized ketenes and 5,6-dihydropyrazin-2(1*H*)-ones **1** in excellent yields and with complete stereocontrol induced by the piperazine system. Subsequent methanolysis of the four-membered ring produces enantiopure 2-oxopiperazine-3-acetic acid methyl esters **7** in good yields.

Acknowledgments

This research was supported by DGI MEC (Grants BQU2003-02921 and CTQ2005-04632/BQU). We thank JANSSEN-CILAG for generous additional support and CAM for a doctoral fellowship to A.F.

References and notes

- For a review, see: (a) Dismore, C. J.; Beshore, D. C. *Tetrahedron* **2002**, *58*, 3297–3312; For recent references, see: (b) Williams, A. J.; Chakthong, S.; Gray, D.; Lawrence, R. M.; Gallagher, T. *Org. Lett.* **2003**, *5*, 811–814; (c) Prenzel, A. H. G. P.; Deppermann, N.; Maison, W. *Org. Lett.* **2006**, *8*, 1681–1684; (d) Roszkowski, P.; Maurin, J. K.; Czarnocki, Z. *Tetrahedron: Asymmetry* **2006**, *17*, 1415–1419.

- (a) Bhatt, U.; Mohamed, N.; Just, G. *Tetrahedron Lett.* **1997**, *38*, 3679–3682; (b) Abelman, M. M.; Fisher, K. J.; Doerffler, E. M.; Edwards, P. J. *Tetrahedron Lett.* **2003**, *44*, 1823–1826; (c) Kogan, T. P.; Rawson, T. E. *Tetrahedron Lett.* **1992**, *33*, 7089–7092.
- (a) Dutta, P. L.; Foye, W. O. *J. Pharm. Sci.* **1990**, *79*, 447–452; (b) Kitamura, S.; Fukushi, H.; Miyawaki, T.; Kawamura, M.; Konishi, N.; Terashita, Z.; Naka, T. *J. Med. Chem.* **2001**, *44*, 2438–2450.
- (a) Brown, D.; Brown, G. A.; Andrews, M.; Large, J. M.; Urban, D.; Butts, C. P.; Hales, N. J.; Gallagher, T. *J. Chem. Soc., Perkin Trans. 1* **2002**, 2014–2021; (b) Alcaide, B.; Almendros, P. *Chem. Soc. Rev.* **2001**, *30*, 226–240; (c) Palomo, C.; Aizpurua, J. M.; Ganboa, I.; Oiarbide, M. *Synlett* **2001**, 1813–1826.
- For a review, see: (a) Gómez-Gallego, M.; Mancheño, M. J.; Sierra, M. A. *Tetrahedron* **2000**, *56*, 5743–5774; (b) Van Brabant, W.; Vanwalleghem, M.; D'hooghe, M.; De Kimpe, N. *J. Org. Chem.* **2006**, *71*, 7083–7086; (c) Palomo, C.; Ganboa, I.; Cuevas, C.; Boschetti, C.; Linden, A. *Tetrahedron Lett.* **1997**, *38*, 4643–4646; (d) Alcaide, B.; Almendros, P.; Aragoncillo, C.; Redondo, M. C.; Torres, M. R. *Chem. Eur. J.* **2006**, *12*, 1539–1546.
- Leading references for chiral acid chlorides: (a) Alcaide, B.; Rodríguez-Vicente, A. *Tetrahedron Lett.* **1999**, *40*, 2005–2006; (b) Muller, M.; Bur, D.; Tschamber, T.; Streit, J. *Helv. Chim. Acta.* **1991**, *74*, 767–773; selected references for chiral imines: (c) Del Buttero, P.; Molteni, G.; Papagni, A.; Miozzo, L. *Tetrahedron: Asymmetry* **2004**, *15*, 2555–2559; (d) Nagao, Y.; Kumagai, T.; Takao, S.; Abe, T.; Ochiai, M.; Inoue, Y.; Taga, T.; Fujita, E. *J. Org. Chem.* **1986**, *51*, 4737–4739.
- López-Rodríguez, M. L.; Morcillo, M. J.; Fernández, E.; Benhamú, B.; Tejada, I.; Ayala, D.; Viso, A.; Campillo, M.; Pardo, L.; Delgado, M.; Manzanares, J.; Fuentes, J. A. *J. Med. Chem.* **2005**, *48*, 2548–2558.
- (a) Viso, A.; Fernández de la Pradilla, R.; López-Rodríguez, M. L.; García, A.; Tortosa, M. *Synlett* **2002**, 755–758; (b) Viso, A.; Fernández de la Pradilla, R.; García, A.; Flores, A.; Tortosa, M.; López-Rodríguez, M. L. *J. Org. Chem.* **2006**, *71*, 1442–1448; (c) Viso, A.; Fernández de la Pradilla, R.; García, A.; Guerrero-Strachan, C.; Alonso, M.; Tortosa, M.; Flores, A.; Martínez-Ripoll, M.; Fonseca, I.; André, I.; Rodríguez, A. *Chem. Eur. J.* **2003**, *9*, 2867–2876.
- Compound **2a**: A mixture of **1a** (0.045 mmol), Et_3N (0.218 mmol) and phthalimidoacetyl chloride (0.078 mmol) in CH_2Cl_2 (10 mL/mmol) at room temperature, was stirred until disappearance of **1a** (TLC) and then diluted with CH_2Cl_2 (10 mL/mmol). The mixture was quenched with brine (7 mL/mmol). The aqueous phase was extracted with CH_2Cl_2 (2×10 mL/mmol) and the combined organic extracts were dried over Na_2SO_4 and concentrated under reduced pressure to give a crude product. Compound **2a** (25 mg, 99%) was obtained after purification by column chromatography (10–30% EtOAc–hexane) as a white foam. Data for **2a**: $R_f = 0.17$ (30% EtOAc–hexane). $[\alpha]_D^{20} +9.9$ (c 1.01, CHCl_3). ^1H NMR (CDCl_3 , 400 MHz) δ 0.12 (s, 3H, TBDMS), 0.14 (s, 3H, TBDMS), 0.47 (d, 3H, $J = 6.4$ Hz, *i*-Pr), 0.91 (s, 9H, TBDMS), 1.06 (d, 3H, $J = 6.8$ Hz, *i*-Pr), 1.57–1.65 (m, 1H, *i*-Pr), 3.40 (dd, 1H, $J = 7.0$, 3.7 Hz, H-3), 3.53 (d, 1H, $J = 10.6$ Hz, H-2), 3.68 (dd, 1H, $J = 10.4$, 7.0 Hz, CH_2O), 3.73 (d, 1H, $J = 14.3$ Hz, CH_2Ph), 3.73 (dd, 1H, $J = 10.4$, 3.7 Hz, CH_2O), 4.49 (d, 1H, $J = 2.6$ Hz, H-6), 5.47 (d, 1H, $J = 2.7$ Hz, H-7), 5.62 (d, 1H, $J = 14.5$ Hz, CH_2Ph), 7.24–7.26 (m, 2H, Ar-H), 7.29–7.36 (m, 3H, Ar-H), 7.74 (dd, 2H, $J = 5.5$, 3.1 Hz, Ar-H), 7.86 (dd, 2H, $J = 5.5$, 3.1 Hz, Ar-H). ^{13}C NMR (CDCl_3 , 75 MHz) δ –5.5, –5.4, 18.5,

- 19.0, 19.6, 25.9, 27.4, 48.2, 53.2, 56.1, 58.5, 58.6, 63.4, 123.7 (2C), 128.2, 128.8 (2C), 128.9 (3C), 131.7, 134.5 (2C), 136.3, 164.8 (2C, CO-Phth), 166.2 (CO), 166.6 (CO). IR (film): 2955, 2925, 2854, 1773, 1724, 1657, 1450, 1389, 1254, 1105, 1044, 834, 716 cm^{-1} . MS (ES): 1145 $[\text{2M}+\text{Na}]^+$, 584 $[\text{M}+\text{Na}]^+$, 562 $[\text{M}+1]^+$ (100%).
10. The absolute configuration of C-3 was established by 2D-NOESY of **3f'**.
11. Under basic conditions and long reaction times, **1b** undergoes isomerization of the C=N bond to conjugation with the naphthyl group. However, this isomerization is not observed under Staudinger conditions.
12. Raising the reaction temperature could either prevent formation of the β -lactam or facilitate its cleavage or decomposition.
13. Compound **2g**: 2D-NOESY showed cross points between H-6/H-7, H-6/Ar-H (H-2, H-3 Naph, 7.31 ppm), H-2/CH₂O, H-2/Ar-H (H-8 Naph, 7.94 ppm).
14. For a recent reference dealing with the stereochemistry of the Staudinger reaction, see: Jiao, L.; Liang, Y.; Xu, J. *J. Am. Chem. Soc.* **2006**, *128*, 6060–6069.
15. Compound **7a**: From a solution of **2a** (32 mg, 0.056 mmol) and TMSCl (0.570 mmol) in MeOH (67 h), **7a** (16 mg, 60%) was isolated as a colorless oil after purification through SCX resin and column chromatography (10–20% EtOAc–CH₂Cl₂). $R_f = 0.33$ (40% EtOAc–CH₂Cl₂). $[\alpha]_D^{20} +53.2$ (c 0.38, CHCl₃). ¹H NMR (CDCl₃, 400 MHz) δ 0.41 (d, 3H, $J = 6.4$ Hz, *i*-Pr), 0.87 (d, 3H, $J = 6.6$ Hz, *i*-Pr), 1.54 (br s, 1H, NH), 1.62–1.69 (m, 1H, *i*-Pr), 2.59 (d, 1H, $J = 10.7$ Hz, H-6'), 3.28 (ap t, 1H, $J = 3.3$ Hz, H-5'), 3.74 (s, 1H, OCH₃), 3.74 (dd, 1H, $J = 11.4, 3.2$ Hz, CH₂O), 3.96 (d, 1H, $J = 14.6$ Hz, CH₂Ph), 3.99 (d, 1H, $J = 3.9$ Hz, H-2'), 4.02 (dd, 1H, $J = 11.1, 4.7$ Hz, CH₂O), 5.42 (d, 1H, $J = 14.6$ Hz, CH₂Ph), 5.91 (d, 1H, $J = 3.9$ Hz, H-2), 7.27 (m, 5H, Ar-H), 7.73 (dd, 2H, $J = 5.5, 2.9$ Hz, Ar-H), 7.88 (dd, 2H, $J = 5.5, 2.9$ Hz, Ar-H). ¹³C NMR (CDCl₃, 100 MHz) δ 18.8, 19.6, 25.8, 48.6, 52.7, 54.7, 55.5, 55.6, 59.8, 63.8, 123.8 (2C), 127.8, 128.6 (3C), 128.7 (2C), 131.8, 134.3 (2C), 136.9, 166.9, 167.9, 168.4 (3C, CO-Phth, CO-N). IR (film): 3356, 2925, 1748, 1719, 1645, 1449, 1436, 1387, 1247, 1109, 1069, 1047 cm^{-1} . MS (ES): 981 $[\text{2M}+\text{Na}]^+$, 512 $[\text{M}+\text{MeOH}+1]^+$, 480 $[\text{M}+1]^+$ (100%).